학술논문

BASELINE CHARACTERISTICS FROM A PHASE 3, RANDOMIZED CONTROLLED TRIAL (COUGH-2) OF GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST, IN REFRACTORY OR UNEXPLAINED CHRONIC COUGH
Document Type
Abstract
Source
In Chest June 2020 157(6) Supplement:A4-A4
Subject
Language
ISSN
0012-3692